General reasons

In today's global life science market we see increased worldwide pricing pressures, narrow windows of exclusivity, saturated drug classes, over-capacity in sales force teams, limited access to doctors, growing generic competition, growing patient power and greater regulatory influence, all of which means there is reduced margin for error and each business decision is more critical in maintaining future corporate well-being.

We see these market pressures surface in a range of client issues:

• A global pharmaceutical company is investing in a breakthrough product but in a crowded well-served market and needs to model the possible outcomes from its development activity to justify future investment.



• An emerging biotech company is in need of advice on how to go to the market with its technology platform.



• A mature biotechnology company is entering important next stages of its evolution and is interested in getting their core messages and branding right.



• A local marketing-focused pharmaceutical company is looking for business intelligence support and market-building programs.



• A large US based biotech company is considering acquiring a European biotech company to boost their late stage pipeline shortfall requiring transaction support, including specialist due diligence and structuring advice and valuation support.

• Limited resources
  • Some companies try to assemble an in-house project team but run into delays due to their employees being already overloaded with their day-to-day responsibilities.


• Objectivity
  • Once the in-house team does come up with a solution it is often biased due to previous involvement and internal political issues.


• Transparency of cost and time
  • We often find that internal projects have ended up costing more than the original plans due to cost creep and lack of transparency of costing.


• External help
  • When companies do engage external firms to help them they find sometimes, with a big generalist company, they get a lot of 'Cut & Paste' projects, which are largely done by juniors, who lack the depth of specialised business and medical knowledge to make a big impact. Or on the other hand they get companies who are super specialised in one functional area without the appreciation of how their findings will influence the big picture - such as market research-only agencies, business development-only, etc.

• Lifescience Dynamics merges strategic thinking with exceptional creative prowess supported by qualitative and quantitative analyses resulting in pragmatic solutions.



• We provide you with an independent, expert view, which is invaluable when assessing complex issues such as the investment in an asset, for repositioning or restructuring of an underperforming asset or the development of a new asset.



• We have a depth of expertise in the field via our associate network from both sides of the table - industry and consulting.